Sign in
Not yet taking people in Costa RicaNo phase

Building an AI tool to detect eye diseases using existing eye images

Tests an AI system for spotting eye diseases in existing images from Costa Rica.

Key facts

Who runs it
Marisse Masis-Solano
Where
Heredia and San José, Costa RicaSee the 2 sites
Trial code
Registry title
Artificial Intelligence-assisted Diagnosis in Ophthalmology
Status
Not yet recruiting
People taking part
15,000 people, planned
Started
1 May 2026
Expected to end
1 May 2029
Type of study
Observational
Treatments tested
  • No interventions
Record updated
1 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

This study uses existing eye images from adults, taken during routine care at two eye centers in Costa Rica. No new people are recruited. The images are used to build an AI tool.

Age
18 years or older when the image was taken
Sex
All sexes
Disease stage
Images of eyes with glaucoma, cataract, diabetic retinopathy or other retinal disease. Images of healthy eyes are also used as controls.
Earlier treatment
Images of eyes with intraocular surgery in the last 3 months, or with recent laser treatment, are left out.

Main reasons for not taking part

  • Eye surgery inside the eye in the last 3 months
  • Severe eye injury that changes the eye's structure
  • Rare or unique eye diseases
  • Recent laser treatment
  • Poor image quality, duplicate images, or missing or wrong data

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Image corresponds to patient ≥18 years of age at time of capture
  • Image modality is one of: fundus photography, posterior segment OCT, anterior segment photography, automated perimetry, or video-OCT
  • Image quality sufficient for diagnostic interpretation (adequate resolution, focus, illumination, complete visualization of anatomical area of interest, no major artifacts)
  • Minimum clinical data available (age or age group, sex, and diagnosis or clinical indication)
  • Image captured during routine clinical care (not specifically for research)
  • No patient objection to use of medical data for research (when applicable per center policy)

Who cannot take part

  • Images from eyes with recent intraocular surgery (<3 months)
  • Images in non-standard or corrupted formats that cannot be processed; Sex/Gender: All Minimum Age: 18 Years Maximum Age: No limit Accepts Healthy Volunteers: Yes (images of healthy eyes without pathology are included as controls)
  • CLINICAL:
  • Images from eyes with severe ocular trauma distorting anatomy
  • Images from patients with rare or unique ocular pathologies not allowing generalization
  • Images post-recent laser treatment where acute changes may confuse analysis; TECHNICAL:
  • Severely degraded image quality (extreme blur, severe under/overexposure, major artifacts preventing interpretation)
  • Duplicate images of same eye on same date
  • Images with missing or clearly erroneous metadata

Where in Costa Rica

  • Centro OcularHeredia, Costa RicaContact: Erick Hernandez, MDNot yet recruiting
  • Asociados de Mácula y Vítreo de Costa RicaSan José, Costa RicaContact: Lihteh Lihteh Wu, MDNot yet recruiting

About the trial

What the trial wants to find out

This is a retrospective, multicenter, observational study designed to develop and validate an artificial intelligence (AI) system capable of detecting and classifying major ophthalmic diseases (glaucoma, cataract, diabetic retinopathy, and other retinal pathologies) in the Costa Rican population. The study will use approximately 15,000 existing medical images from digital archives of two ophthalmic centers in Costa Rica, without active participant recruitment or capture of new images.

Read full original descriptionShow less

The primary motivation is that AI systems developed in other countries (primarily Asian, European, or North American populations) do not necessarily perform with the same accuracy when applied to Latin American populations. This study seeks to establish a precedent for the importance of locally validating any medical AI technology before clinical implementation.

The group in the trial

  • Images of patients over 18 years old

    This is a diagnostic validation study without intervention. All images are analyzed using the same methodology. There are no comparison groups, treatment arms, or cohorts. The study evaluates AI system performance against expert ophthalmologist diagnoses (ground truth).

    Treatment: No interventions

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development and Validation of an Artificial Intelligence-assisted Diagnostic System for Ophthalmic Pathologies
Plain-language title
Building an AI tool to detect eye diseases using existing eye imagesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
1 April 2026